PrecISE is different because it is a study to learn what treatments are best for each person, instead of only people with the most common types of asthma. This individual-based care is called precision medicine, a new approach to care based on someone’s medical history, where they live, and profile (age, gender, and so on). We will use precision medicine to understand treatments for severe asthma. These treatments are not yet used for asthma today.

Your patients may qualify for this first of its kind study if they:

- Are age 12 and up.
- Have severe asthma as defined by commonly accepted guidelines.
- Currently have uncontrolled asthma, or worsening asthma & attacks.
- Are on a stable regimen of asthma medications.
- Are not pregnant and not breastfeeding.
- Are not taking part in other clinical trials.

These are a few examples of criteria that will apply. Contact us for more details: preciseasthma.org

A New Type of Asthma Study

PrecISE is different because it is a study to learn what treatments are best for each person, instead of only people with the most common types of asthma.

What people with severe asthma are saying about PrecISE:

“I think it’s a brilliant idea.”

“I would love to share with the broader community of severe asthmatics that this is actually taking place.”

PrecISE is a network of leading universities, medical doctors, and scientists dedicated to helping people living with severe asthma.

Visit preciseasthma.org

Supported by the National Heart, Lung, and Blood Institute (NHLBI)

Severe Asthma is different for everyone.

How can you help?

The PrecISE research study is asking you to help us in discovering more effective ways to treat patients with severe asthma.

Join a severe asthma study unlike any other.

Date of Approval: 02/25/2020
Severe Asthma...

...can be difficult to control. About 10-15 percent of people living with asthma have severe asthma. Symptoms and effects on the body are different for each person, making severe asthma difficult to treat.

PrecISE is an opportunity for you to contribute to the discovery of more effective ways to treat patients with severe asthma. We will be testing new treatments in adolescents and adults.

We have two goals for the PrecISE study:

1. Make it easier to identify different types of severe asthma.
2. Understand the best ways to treat these different types of severe asthma.

Benefits & Risks

We inform potential participants of any known risks before they join the study.

While participants will receive treatments, that does not mean the treatments have been found to be effective for asthma. At least once, patients will receive a placebo.

This research is completely voluntary. Patients can stop participating at any time.

The PrecISE Clinical Trial

- Multiple treatments will be tested in a placebo controlled randomized trial
- Each participant will receive between 1 and 6 treatments
- Treatment periods will each last 16 weeks, requiring monthly visits
- If they choose, participants can receive study provided baseline asthma therapies and asthma controller medications.

Time Commitments

Visits: Participants first go to a clinic to complete screening visits to tell us more about them and receive medical tests. Screening visits can take about 2-4 hours and may be split over different days.

If a participant is eligible for the study, they will take part in treatment visits (about 2 hours each). At these visits, we do medical tests and give out study treatments to use at home.

Study Commitment: The length of time a participant is in the study will range from 1 to 3.5 years, and it will depend on the date of enrollment. If enrolled early in the study, and qualified for each individual treatment, participants could receive up to 5 treatments.

Home Activities: We will ask participants to spend time at home taking measurements and tracking how study treatments affect their asthma.

Reminders: Time slots for these visits will be flexible, and participants will receive appointment reminders.

Compensation

- All research visits will be completed at no charge.
- No research-related visits will be billed to health insurance.
- Participants will be compensated for their time.

Date of Approval: 02/25/2020